SERB Pharmaceuticals has announced the acquisition of Y-mAbs Therapeutics.

赛尔布制药公司宣布收购Y-mAbs治疗公司。

The agreement values Y-mAbs at approximately $412 million in an all-cash transaction.

该协议在全现金交易中对Y-mAbs的估值约为4.12亿美元。

Under the terms of the deal, SERB will launch a tender offer to purchase all outstanding shares of Y-mAbs common stock at $8.60 per share. This offer represents a premium of around 105 per cent compared to Y-mAbs’ closing share price on 4 August 2025, the last trading day before the announcement.

根据协议条款，SERB将发起要约收购，以每股8.60美元的价格购买Y-mAbs所有已发行的普通股。此报价较Y-mAbs在2025年8月4日（公告前的最后一个交易日）的收盘价溢价约105%。

The Y-mAbs Board of Directors unanimously approved the transaction after reviewing various strategic alternatives to maximise shareholder value. This process involved discussions with multiple potential buyers and consideration of additional capital options to support the company’s development pipeline..

Y-mAbs 董事会一致批准了该交易，此前已审阅了多种战略选择以最大程度地提升股东价值。这一过程涉及与多个潜在买家进行讨论，并考虑了支持公司研发管线的额外资金选项。

Y-mAbs is known for developing DANYELZA® (naxitamab-gqgk), the first FDA-approved treatment for relapsed or refractory high-risk neuroblastoma. This rare and aggressive paediatric cancer typically affects children and young adults. The therapy, administered either in hospital or in outpatient settings, has expanded treatment options for neuroblastoma patients and their families..

Y-mAbs因开发DANYELZA®（naxitamab-gqgk）而闻名，这是首个获FDA批准用于治疗复发或难治性高危神经母细胞瘤的疗法。这种罕见且侵袭性的儿童癌症通常影响儿童和年轻成人。该疗法既可以在医院内施用，也可以在门诊环境中进行，为神经母细胞瘤患者及其家庭拓展了治疗选择。

Alongside DANYELZA, Y-mAbs’ pipeline includes early-stage investigational therapies, notably through its SADA pretargeted radioimmunotherapy platform. These include potential treatments targeting GD2 in solid tumours and CD38 in circulating tumours.

与DANYELZA一起，Y-mAbs的管线包括早期研究性疗法，特别是通过其SADA预靶向放射免疫治疗平台。这些疗法包括针对实体瘤中的GD2和循环肿瘤中的CD38的潜在治疗方法。

For SERB, the acquisition is expected to enhance its rare oncology portfolio, which already includes Voraxaze®, Vistogard®, and Xermelo®. The company aims to utilise its global footprint and expertise to support the wider availability of DANYELZA and continue developing Y-mAbs’ pipeline.

对于SERB来说，此次收购预计将增强其已包含Voraxaze®、Vistogard®和Xermelo®的罕见肿瘤学产品组合。该公司旨在利用其全球影响力和专业知识，支持DANYELZA的更广泛可用性，并继续开发Y-mAbs的产品管线。

The acquisition is aligned with SERB’s broader strategy of expanding its presence in rare disease and oncology markets, particularly in the United States, where it has been building its operations over the past five years.

该收购与SERB更广泛的策略一致，即扩大其在罕见病和肿瘤学市场的影响力，尤其是在美国市场。过去五年中，SERB一直在美国拓展其业务。

Source: serb.com

来源：serb.com